BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) appointed Uzair Qadeer as its first chief diversity officer. Previously, he served the rare diseases company as VP, head of enterprise partnership. His appointment comes as BIO rolls out its BIOEquality...
BioCentury | Jul 27, 2020
Deals

AZ goes early for its latest $1B ADC deal with Daiichi

With the success of Enhertu as the template, AstraZeneca is putting at least a further $1 billion on the line for a much earlier stage ADC in a new deal with Daiichi Sankyo. AstraZeneca plc...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

BioNTech prices upsized financing BioNTech SE (NASDAQ:BNTX) raised $511.5 million in an upsized offering through the sale of 5.5 million ADSs at $93 per ADS. The deal, which had been slated for 5 million ADSs,...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...
BioCentury | May 30, 2020
Product Development

ASCO data bring new markets within reach for two AstraZeneca therapies

AstraZeneca stole the show at ASCO on Friday with data that should help propel its top-grossing cancer drug and one of its newest market entrants into broadly expanded patient populations, as long as physicians adopt...
BioCentury | Apr 7, 2020
Product Development

April 6 Quick Takes: Second anemia approval for BMS, Acceleron therapy; plus EU approves trio of metabolic disease drugs, Dicerna-Alnylam and Axsome

Reblozyl gets second approval FDA approved Reblozyl luspatercept-aamt from Bristol Myers Squibb Co. (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) to treat anemia in certain patients with myelodysplastic syndromes. It is the second indication for the...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Depletion of the mitochondrial chaperone HspA9 for BRAF-mutant melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Reducing production of the mitochondrial chaperone HspA9 could treat BRAF-mutant melanoma. In melanoma patients, high tumor levels of HspA9 mRNA were associated with poor survival. In two human melanoma cell...
BioCentury | Apr 1, 2020
Deals

AAV tech pays off for Ultragenyx as Daiichi digs into gene therapy

Ultragenyx's AAV manufacturing deal with Daiichi Sankyo highlights the former's return on its investment in Dimension Therapeutics, and the latter's growing interest in gene therapy. The deal, announced Wednesday, gives Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) $125...
BioCentury | Feb 22, 2020
Product Development

Esperion enters crowded LDL-lowering market with FDA approval

FDA’s approval of Nexletol marks Esperion’s transition to a commercial-stage company. Esperion Therapeutics Inc. (NASDAQ:ESPR) plans to launch Nexletol bempedoic acid on March 30. The drug, which is orally administered once-daily, is approved as an...
BioCentury | Jan 28, 2020
Company News

Jan. 27 Company Quick Takes: Enhertu meets in pivotal gastric cancer study; plus Biocon-Mylan, CMS, Lilly-Boehringer, Ningbo-Genentech

Japan submission on horizon for AZ, Daiichi’s ADC Daiichi Sankyo Co. Ltd. (Tokyo:4568) plans to seek approval of Enhertu for gastric cancer starting in Japan after the anti-HER2 antibody-drug conjugate met the primary and a...
Items per page:
1 - 10 of 1472
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) appointed Uzair Qadeer as its first chief diversity officer. Previously, he served the rare diseases company as VP, head of enterprise partnership. His appointment comes as BIO rolls out its BIOEquality...
BioCentury | Jul 27, 2020
Deals

AZ goes early for its latest $1B ADC deal with Daiichi

With the success of Enhertu as the template, AstraZeneca is putting at least a further $1 billion on the line for a much earlier stage ADC in a new deal with Daiichi Sankyo. AstraZeneca plc...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

BioNTech prices upsized financing BioNTech SE (NASDAQ:BNTX) raised $511.5 million in an upsized offering through the sale of 5.5 million ADSs at $93 per ADS. The deal, which had been slated for 5 million ADSs,...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...
BioCentury | May 30, 2020
Product Development

ASCO data bring new markets within reach for two AstraZeneca therapies

AstraZeneca stole the show at ASCO on Friday with data that should help propel its top-grossing cancer drug and one of its newest market entrants into broadly expanded patient populations, as long as physicians adopt...
BioCentury | Apr 7, 2020
Product Development

April 6 Quick Takes: Second anemia approval for BMS, Acceleron therapy; plus EU approves trio of metabolic disease drugs, Dicerna-Alnylam and Axsome

Reblozyl gets second approval FDA approved Reblozyl luspatercept-aamt from Bristol Myers Squibb Co. (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) to treat anemia in certain patients with myelodysplastic syndromes. It is the second indication for the...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Depletion of the mitochondrial chaperone HspA9 for BRAF-mutant melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Reducing production of the mitochondrial chaperone HspA9 could treat BRAF-mutant melanoma. In melanoma patients, high tumor levels of HspA9 mRNA were associated with poor survival. In two human melanoma cell...
BioCentury | Apr 1, 2020
Deals

AAV tech pays off for Ultragenyx as Daiichi digs into gene therapy

Ultragenyx's AAV manufacturing deal with Daiichi Sankyo highlights the former's return on its investment in Dimension Therapeutics, and the latter's growing interest in gene therapy. The deal, announced Wednesday, gives Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) $125...
BioCentury | Feb 22, 2020
Product Development

Esperion enters crowded LDL-lowering market with FDA approval

FDA’s approval of Nexletol marks Esperion’s transition to a commercial-stage company. Esperion Therapeutics Inc. (NASDAQ:ESPR) plans to launch Nexletol bempedoic acid on March 30. The drug, which is orally administered once-daily, is approved as an...
BioCentury | Jan 28, 2020
Company News

Jan. 27 Company Quick Takes: Enhertu meets in pivotal gastric cancer study; plus Biocon-Mylan, CMS, Lilly-Boehringer, Ningbo-Genentech

Japan submission on horizon for AZ, Daiichi’s ADC Daiichi Sankyo Co. Ltd. (Tokyo:4568) plans to seek approval of Enhertu for gastric cancer starting in Japan after the anti-HER2 antibody-drug conjugate met the primary and a...
Items per page:
1 - 10 of 1472